康希诺生物(06185.HK)脑膜炎疫苗“曼海欣”扩大适用人群年龄范围申请获受理

阿斯达克财经
Jul 20

康希诺生物(06185.HK) 公布,已获中国国家药品监督管理局出具之受理通知书,受理将ACYW135群脑膜炎球菌多糖结合疫苗(CRM197载体)“曼海欣”的适用人群年龄范围,由“3月龄到6周岁(83月龄)儿童”扩大至“3月龄到17周岁人群”的补充申请。“曼海欣”为中国首个脑膜炎球菌四价结合疫苗产品,于2021年12月获批上市,并于2026年2月将适用年龄范围扩大至6周岁儿童。(gc/u)(港股...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10